Veeda Clinical Research refiles DRHP for IPO with Sebi
Prospectus (DRHP) with capital markets regulator, Securities and Exchange Board of India (SEBI) to raise funds through Initial Public Offering (IPO).
The company had earlier filed its IPO papers with Sebi on September 27, 2021. The IPO, with a face value of Rs 2, is a mix of fresh issue of shares up to Rs 185 crore and an offer-for-sale up to 13 million equity shares by Promoter and Other Selling Shareholders.
Offer for sale consists of shareholders selling shares up to 3,493,895 equity shares by Basil Private Limited, up to 7,359,620 equity shares by Bondway Investments Inc., up to 810,000 equity shares by Dr. S N Vinaya Babu, up to 690,210 equity shares by Sabre Partners AIF Trust, up to 198,795 equity shares by CX Alternative Investment Fund, up to 210,570 equity shares by Anushka Singh, up to 81,694 equity shares by Vikrampati Singhania, up to 40,847 equity shares by Harsh Pati Singhania, up to 40,487 equity shares by Anshuman Singhania, and up to 34,000 equity shares by Siddharth Ramesh Kejriwal.
The company, in consultation with the BRLMS, may consider a further issue of equity shares through a private placement, preferential allotment or any other method aggregating up to Rs 37 crore as pre-IPO placement. If the pre-IPO placement is completed, the amount raised under the pre-IPO placement will be reduced from the fresh issue.
The proceeds from the fresh issue to the extent of Rs 50 crore will be used for capital expenditure towards procurement of equipment and machinery for the company; Rs 35 crore for
